Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin

• Main Authors: G. R. Foster, S. Zeuzem, S. Pianko, S. K. Sarin, T. Piratvisuth, S. Shah, P. Andreone, A. Sood, W. L. Chuang, C. M. Lee, J. George, M. Gould, R. Flisiak, I. M. Jacobson, P. Komolmit, S. Thongsawat, T. Tanwandee, J. Rasenack, R. Sola, I. Messina, Y. Yin, S. Cammarata, G. Feutren, K. K. Brown
• Format: Journal
• Published: 2018
• Subjects: Immunology and Microbiology; Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84875216158&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/52647
• Institution: Chiang Mai University

Rare interstitial lung disease cases have been reported with albinterferon alfa-2b (albIFN) and pegylated interferon alfa-2a (Peg-IFNα-2a) in chronic hepatitis C virus (HCV) patients. Systematic pulmonary function evaluation was conducted in a study of albIFN q4wk vs Peg-IFNα-2a qwk in patients with...